Episode

Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes

Podcast
Cell & Gene: The Podcast
Published
Jan 29, 2026
Duration seconds
1803
Processing state
not_requested
Canonical source
https://www.buzzsprout.com/1810482/episodes/18570523-building-safer-crispr-medicines-for-cvd-with-scribe-therapeutics-benjamin-oakes.mp3
Audio
https://www.buzzsprout.com/1810482/episodes/18570523-building-safer-crispr-medicines-for-cvd-with-scribe-therapeutics-benjamin-oakes.mp3
JSON
/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/building-safer-crispr-medicines-for-cvd-with-scribe-therapeutics-benjamin-oakes
Markdown
/podcast/cell-gene-the-podcast-4048431/building-safer-crispr-medicines-for-cvd-with-scribe-therapeutics-benjamin-oakes.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/building-safer-crispr-medicines-for-cvd-with-scribe-therapeutics-benjamin-oakes/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/cell-gene-the-podcast-4048431/building-safer-crispr-medicines-for-cvd-with-scribe-therapeutics-benjamin-oakes.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

We love to hear from our listeners. Send us a message. In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications. Oakes shares Scribe’s engineered CasX platform and epigenetic silencers, preclinical data from its various programs, and why exquisite specificity and low-dose ...